Lucia Chmelova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lucia Chmelova has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Alastair Thompson
1 shared publication- Amit Agrawal
Department of Surgery, University of Cambridge, Cambridge, UK
1 shared publication - Andrea Degasperi
Department of Genomic Medicine, University of Cambridge, Cambridge, UK
1 shared publication Andrew Futreal
1 shared publication- Anna Ehinger
Lund University Hospital, Clinical Genetics, Pathology and Molecular Diagnostics Lund Sweden
1 shared publication Daniel Rea
1 shared publication
Latest Publications
- Open Access
- 19 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
High-depth whole genome sequencing of premalignant breast lesions reveals rearrangement hotspots and personalized management opportunities
Ductal carcinoma in situ is a non-obligate precursor lesion of breast cancer. Often detected by mammography, most cases are managed through surgical and/or radiotherapy approaches. Today, it is not possible to predict which patients will progress to invasive disease. Here, we evaluate high-depth whole-genome sequenced ductal carcinoma in situ, enriched for high-grade clinical lesions, to understand whether deep WGS could reveal biological insights and/or personalized therapeutic vulnerabilities that may be targetable. We find genomic locations that are likely susceptible to producing the initiating lesion for structural variations prone to subsequent evolution, termed SHOREs. We additionally highlight individualized therapeutic potential that would otherwise not be appreciable without whole genome sequencing. We posit that holistic whole genome sequencing profiling could offer a more precise stratification approach, discerning higher-risk cases for prospective clinical studies on personalized therapies, from truly low-risk cases suitable for active monitoring.
- 19 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessHigh-depth whole genome sequencing of premalignant breast lesions reveals rearrangement hotspots and personalized management opportunities
Ductal carcinoma in situ is a non-obligate precursor lesion of breast cancer. Often detected by mammography, most cases are managed through surgical and/or radiotherapy approaches. Today, it is not possible to predict which patients will progress to invasive disease. Here, we evaluate high-depth whole-genome sequenced ductal carcinoma in situ, enriched for high-grade clinical lesions, to understand whether deep WGS could reveal biological insights and/or personalized therapeutic vulnerabilities that may be targetable. We find genomic locations that are likely susceptible to producing the initiating lesion for structural variations prone to subsequent evolution, termed SHOREs. We additionally highlight individualized therapeutic potential that would otherwise not be appreciable without whole genome sequencing. We posit that holistic whole genome sequencing profiling could offer a more precise stratification approach, discerning higher-risk cases for prospective clinical studies on personalized therapies, from truly low-risk cases suitable for active monitoring.